Uniunea Europeană - slovacă - EMA (European Medicines Agency)

nordic group b.v. - metotrexát - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antineoplastické činidlá - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - abatacept - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid - imunosupresíva - reumatoidná arthritisorencia, v kombinácii s metotrexátom, je indikovaný na:liečbu stredne ťažkou až ťažkou aktívnou reumatoidnou artritídou (ra) u dospelých pacientov, ktorí reagovali neadekvátne na predchádzajúcu liečbu jedným alebo viac chorôb-úprava anti-reumatické drogy (dmards) vrátane metotrexát (mtx), alebo nádor nekrotizujúci faktor (tnf)-alfa inhibítor. liečbu vysoko aktívne a progresívne ochorenie u dospelých pacientov s reumatoidnou artritídou, ktoré predtým neboli liečení metotrexátom. zníženie progresie poškodenia kĺbov a zlepšenie fyzickej funkcie boli preukázané počas kombinácii ošetrenia s abatacept a metotrexátom. psoriatická arthritisorencia, samostatne alebo v kombinácii s metotrexátom (mtx), je indikovaná na liečbu aktívnej psoriatická artritída (psa) u dospelých pacientov, ak odpoveď na predchádzajúcu dmard terapie vrátane mtx bola neprimeraná, a pre koho ďalšie systémovej liečby psoriázy kožné lézie, nie je potrebné. polyartikulárnou juvenilnou idiopatickou arthritisorencia v kombinácii s metotrexátom je indikovaný na liečbu stredne ťažkou až ťažkou aktívnou polyartikulárnou juvenilnou idiopatickou artritídou (pjia) v pediatrických pacientov 2 rokov veku a starších, ktorí mali nedostatočnú odpoveď na predchádzajúcu dmard terapia. orencia sa môže podávať ako monotherapy v prípade intolerancie na metotrexát, alebo keď sa liečba metotrexátom nevhodné.

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastické činidlá - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. len obmedzené údaje o účinnosti a bezpečnosti pacientov v minulosti liečených monoklonálne protilátky, vrátane rituximab alebo pacientov, žiaruvzdorné na predchádzajúcu rituximab plus chemoterapia. pozri časť 5. 1 pre ďalšie informácie. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab bolo preukázané, že znižujú rýchlosť progresie poškodenia kĺbov, merané podľa x-ray a zlepšiť fyzickú funkciu, keď uvedené v kombinácii s metotrexátom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - topiramát - 21 - antiepileptica, anticonvulsiva

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - topiramát - 21 - antiepileptica, anticonvulsiva

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - topiramát - 21 - antiepileptica, anticonvulsiva

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - topiramát - 21 - antiepileptica, anticonvulsiva

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - topiramát - 21 - antiepileptica, anticonvulsiva

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - topiramát - 21 - antiepileptica, anticonvulsiva